June 29, 2016
Recommended Topic Related To:

Arzerra

"The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

MCL is a rare form of non-Hodgkin lymphoma and represents about 6 "...

A A A

Arzerra




PATIENT INFORMATION

Advise patients to contact a healthcare professional for any of the following:

  • Signs and symptoms of infusion reactions including fever, chills, rash, or breathing problems within 24 hours of infusion [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS]
  • Symptoms of hepatitis including worsening fatigue or yellow discoloration of skin or eyes [see WARNINGS AND PRECAUTIONS]
  • New neurological symptoms such as confusion, dizziness or loss of balance, difficulty talking or walking, or vision problems [see WARNINGS AND PRECAUTIONS]
  • Bleeding, easy bruising, petechiae, pallor, worsening weakness, or fatigue [see WARNINGS AND PRECAUTIONS]
  • Signs of infections including fever and cough [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS]
  • Pregnancy-Advise pregnant women of potential fetal B-cell depletion [see Use in Specific Populations]

Advise patients of the need for:

Last reviewed on RxList: 1/27/2016
This monograph has been modified to include the generic and brand name in many instances.

Arzerra - User Reviews

Arzerra User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Arzerra sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.